ClinicalTrials.gg
CompletedNCT02041195Updated Aug 7, 2023Results posted

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

A Phase 1/2 interventional study of Setmelanotide and Placebo in Overweight and Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-07.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
5th of 16
99 · median 34
Started
2014
the only one that year
Phase 1/2
Only one
of the 16
Registered
2nd of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one is the 5th largest by enrollment, is the only one that started in 2014, is the only one in phase 1/2, and was the 2nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss parameters, as well as pharmacokinetic (PK) profile. The study is designed to evaluate the efficacy and tolerability of setmelanotide administered once or twice daily. The study drug (setmelanotide and placebo) will be administered in a blinded fashion.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

Keywords

  • Overweight
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 99 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between the ages of 18 and 65 years, inclusive.
  • Able to provide voluntary, written with comprehension of all aspects of the protocol, prior to any study procedures.
  • In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities.
  • : 30 to 40 Kg/m2.
  • Stable body weight by participant report (+/- 5 Kg) during previous 6 months.
  • Blood pressure (\<140/90 mmHg); may include stable dose (≥ 30 days of use) of up to two anti-hypertensive medications to achieve control and that are intended to remain on a stable dose during the protocol.
  • Willingness (during screening) and demonstrated ability (as witnessed in the clinic prior to randomization) to self-administer study medication subcutaneously via a once or twice daily SC injection using a small insulin syringe.
  • Willing to maintain a healthy diet and exercise regime throughout study as recommended by counseling at study start.
  • Female participants must have negative serum pregnancy test and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method (i.e., sponge), or a double-barrier method of (i.e., condom with spermicide) or abstinence must be used/ practiced throughout the study and for 90 days following the study.
  • Females of non-, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or for at least 12 months (and confirmed with a screening FSH level in the post-menopausal lab range), do not require contraception during the study.
  • Males with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study and for 90 days following the study. Male participants must not donate sperm for 90 days following their participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Fasting blood glucose > than 140 mg/dL.
  • TSH level outside the normal range.
  • Creatinine > 1.5 times the .
  • Liver function tests > 2 times the upper limit of normal.
  • Active or history of any significant medical condition including renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic or hematological disease.
  • Patients with a history of the following:

    1. Uncontrolled hypertension;
    2. Diabetes requiring medical treatment;
    3. Major depressive disorder within the last 2 years;
    4. Any lifetime history of a suicide attempt;
    5. Any suicidal ideation/behavior in the last month;
    6. Other severe psychiatric disorders (e.g. schizophrenia, bipolar disorder, severe eating disorders including bulimia).
  • A PHQ-9 score of ≥15.
  • Any suicidal ideation of type 4 or 5 on the C-SSRS.
  • Prior bariatric surgery.
  • History or close family history (parents or siblings) of melanoma.
  • Significant dermatologic findings as part of the Screening comprehensive skin evaluation performed by the dermatologist.
  • Currently treated with anorectic agents or drugs in last 2 months from screening with anorexia as a frequent side event.
  • Taking more than 2 anti-hypertensive medications.
  • Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the patient or obscure interpretation of laboratory test results or interpretation of study data.
  • History of any , past or present, including skin cancer, multiple severely dysplastic nevi, or nevoid basal cell carcinoma.
  • History of infection or or C.
  • History of significant drug or anaphylaxis.
  • History of hypersensitivity to proteins (e.g., allergy shots).
  • Any abnormalities on screening laboratories as determined by the Investigator.
  • Abnormal 12-lead (ECG) at screening, except minor deviations deemed to be of no clinical significance by the Investigator. must be \< 450 ms.
  • Received any experimental drugs or devices or have participated in a clinical study within 30 days prior to dosing.
  • Blood donation greater than 500 mL within 60 days prior to screening or intent to donate up to 30 days after Final Study Visit.
  • Hospitalization for surgery within the 3 months prior to screening except for minor outpatient procedures, or any planned hospitalizations during the study period.
  • Poor venous access or inability to tolerate venipuncture.
  • Inability to attend all study visits or comply with protocol requirements including fasting and restrictions on concomitant medication intake.
  • Participation in weight loss programs during the study period, including nutritional supplements/ replacements other than as recommended by nutritional counseling provided at study start.
  • Use of prescription medications on a regular basis with the following exceptions:

    1. (must be on for ≥3 months);
    2. Hormone replacement therapy (must be on stable dose for ≥3 months);
    3. Antihypertensives (\<2 medications on a stable dose for ≥ 30 days);
    4. Statins (dose must be ≤ half the maximum dose; must be on a stable dose ≥3 months);
    5. Thyroxin (stable dose for ≥ 30 days);
    6. The last use of any other prescription medication must have been greater than 5 half-lives for the specific medication or at least 14 days prior to randomization, whichever is longer.
  • Women who are pregnant or are breast feeding.
  • Previously randomized and dosed in this study or previously exposed to setmelanotide.
  • History of alcohol or drug abuse within 5 years of Screening Visit.
  • Any other reason, which in the opinion of the Investigator, would confound proper evaluation of the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Active comparator
    Setmelanotide Once Daily

    Once daily in the morning, equivalent placebo in evening.

    Drug: Setmelanotide · Drug: Placebo

  • Active comparator
    Setmelanotide Split Dose

    Split dose, one half in the morning and one half in the evening.

    Drug: Setmelanotide

  • Placebo comparator
    Placebo

    Placebo in the morning, placebo in the evening.

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Body Weight - Stage A

    Time frame: Baseline

  2. Percent Change From Baseline in Body Weight at Week 12 - Stage A

    Time frame: Baseline, Week 12

  3. Body Weight - Stage B

    Time frame: Baseline

  4. Percent Change From Baseline in Body Weight at Week 12 - Stage B

    Time frame: Baseline, Week 12

  5. Body Weight - Stage C

    Time frame: Baseline

  6. Percent Change From Baseline in Body Weight at Week 12 - Stage C

    Time frame: Baseline, Week 12

  7. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A

    An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.

    Time frame: From first dose up to Day 114

  8. Number of Participants With TEAEs - Stage B

    An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.

    Time frame: From first dose up to Day 114

  9. Number of Participants With TEAEs - Stage C

    An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.

    Time frame: From first dose up to Day 114

Secondary outcomes

  1. Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A

    Time frame: Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24 hours after dosing on Day 8

  2. Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C

    Time frame: Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours after dosing on Day 8

  3. Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A

    The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in ABPM parameters (systolic blood pressure \[SBP\], diastolic blood pressure \[DBP\], pulse pressure, mean arterial pressure \[MAP\]) during 24-hour interval between Days 8 and 15 is presented.

    Time frame: Baseline and for one 24-hour interval between Days 8 or 15

  4. Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C

    The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in ABPM parameters (SBP, DBP, pulse pressure, MAP) during 24-hour interval between Days 8 and 15 is presented.

    Time frame: Baseline and for one 24-hour interval between Days 8 or 15

  5. Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A

    The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.

    Time frame: Baseline and for one 24-hour interval between Days 8 and 15

  6. Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C

    The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.

    Time frame: Baseline and for one 24-hour interval between Days 8 and 15

08

Results

Posted Aug 7, 2023

Participant flow

Participant flow — Overall Study
MilestoneStage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QDStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QDStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QD
Started109331162928
Completed86331062225
Not completed23001073
Withdrew: Adverse event12000030
Withdrew: Withdrawal by subject10000043
Withdrew: Unable to comply with study visits01001000

Outcome measures

PrimaryBody Weight - Stage A
Time frame:
Baseline
Reported as:
Mean · Kilograms (kg)
Body Weight - Stage A
Kilograms (kg)Stage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo
Body Weight - Stage A101.7 ± 5.09101.7 ± 4.2494.5 ± 3.85
PrimaryPercent Change From Baseline in Body Weight at Week 12 - Stage A
Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight at Week 12 - Stage A
percent changeStage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo
Percent Change From Baseline in Body Weight at Week 12 - Stage A-1.38 (-3.27 to 0.52)-0.74 (-2.77 to 1.28)2.89 (0.53 to 5.25)
Statistical analysis
  • Stage A: Setmelanotide 0.75 mg BID vs Stage A: Placebo · Longitudinal mixed analysis of variance · p = 0.004 (One sided p-value.) · Least squares (ls) mean difference: -4.26 · 90% CI -6.81 to -1.72A longitudinal mixed analysis of variance model with fixed effects for treatment, timepoint, treatment-by-timepoint, baseline weight as covariate, and participant as random effect was used.
  • Stage A: Setmelanotide 1.5 mg QD vs Stage A: Placebo · Longitudinal mixed analysis of variance · p = 0.012 · Ls mean difference: -3.63 · 90% CI -6.23 to -1.03A longitudinal mixed analysis of variance model with fixed effects for treatment, timepoint, treatment-by-timepoint, baseline weight as covariate, and participant as random effect was used.
PrimaryBody Weight - Stage B
Time frame:
Baseline
Reported as:
Mean · kg
Body Weight - Stage B
kgStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QD
Body Weight - Stage B99.4 ± 3.5193.3 ± 2.92
PrimaryPercent Change From Baseline in Body Weight at Week 12 - Stage B
Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight at Week 12 - Stage B
percent changeStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QD
Percent Change From Baseline in Body Weight at Week 12 - Stage B-1.29 (-2.47 to -0.11)2.28 (0.68 to 3.88)
Statistical analysis
  • Stage B: Setmelanotide 1.5 mg QD vs Stage B: Placebo 1.5 mg QD · Longitudinal mixed analysis of variance · p = <0.001 (One sided p-value.) · Ls mean difference: -3.57 · 90% CI -5.24 to -1.89A longitudinal mixed analysis of variance model with fixed effects for treatment, timepoint, treatment-by-timepoint, baseline weight as covariate, and participant as random effect was used.
PrimaryBody Weight - Stage C
Time frame:
Baseline
Reported as:
Mean · Kg
Body Weight - Stage C
KgStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QD
Body Weight - Stage C98.5 ± 1.8798.7 ± 2.44
PrimaryPercent Change From Baseline in Body Weight at Week 12 - Stage C
Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight at Week 12 - Stage C
percent changeStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QD
Percent Change From Baseline in Body Weight at Week 12 - Stage C-2.28 (-3.32 to -1.25)-0.06 (-1.08 to 0.95)
Statistical analysis
  • Stage C: Setmelanotide 2 mg QD vs Stage C: Placebo 2 mg QD · Longitudinal mixed analysis of variance · p = 0.002 · Ls mean difference: -2.22 · 90% CI -3.44 to -1.00A longitudinal mixed analysis of variance model with fixed effects for treatment, timepoint, treatment-by-timepoint, baseline weight as covariate, and participant as random effect was used.
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.

Time frame:
From first dose up to Day 114
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A
ParticipantsStage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QD
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A10823
PrimaryNumber of Participants With TEAEs - Stage B

An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.

Time frame:
From first dose up to Day 114
Reported as:
Count of participants · Participants
Number of Participants With TEAEs - Stage B
ParticipantsStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QD
Number of Participants With TEAEs - Stage B93
PrimaryNumber of Participants With TEAEs - Stage C

An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.

Time frame:
From first dose up to Day 114
Reported as:
Count of participants · Participants
Number of Participants With TEAEs - Stage C
ParticipantsStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QD
Number of Participants With TEAEs - Stage C2921
SecondaryMean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A
Time frame:
Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24 hours after dosing on Day 8
Reported as:
Mean · nanograms per milliliter (ng/mL)
Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A
nanograms per milliliter (ng/mL)Stage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QD
Predose (0 hours)7.24 ± 2.523.54 ± 0.949
1 hour postdose9.18 ± 3.048.51 ± 3.07
2 hours postdose10.8 ± 3.9313.0 ± 5.75
4 hours postdose13.9 ± 5.0518.0 ± 6.26
6 hours postdose11.8 ± 5.0220.6 ± 5.27
8 hours postdose9.86 ± 3.6619.8 ± 3.19
10 hours postdose7.48 ± 3.1815.5 ± 2.46
12 hours postdose6.02 ± 2.4911.1 ± 1.63
14 hours postdose10.6 ± 5.659.15 ± 1.29
16 hours postdose13.6 ± 6.967.32 ± 1.15
20 hours postdose9.26 ± 3.865.23 ± 0.991
22 hours postdose7.43 ± 3.324.41 ± 0.945
24 hours postdose5.74 ± 2.723.58 ± 0.900
SecondaryMean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C
Time frame:
Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours after dosing on Day 8
Reported as:
Mean · ng/mL
Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C
ng/mLStage C: Setmelanotide 2 mg QD
Predose (0 hours)5.03 ± 1.84
1 hour postdose12.3 ± 3.99
2 hours postdose18.1 ± 6.23
4 hours postdose24.2 ± 8.19
6 hours postdose26.5 ± 7.32
8 hours postdose24.0 ± 5.88
10 hours postdose18.1 ± 3.76
12 hours postdose13.9 ± 3.35
14 hours postdose11.2 ± 2.47
24 hours postdose4.74 ± 1.66
SecondaryChange From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A

The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in ABPM parameters (systolic blood pressure \[SBP\], diastolic blood pressure \[DBP\], pulse pressure, mean arterial pressure \[MAP\]) during 24-hour interval between Days 8 and 15 is presented.

Time frame:
Baseline and for one 24-hour interval between Days 8 or 15
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A
millimeters of mercury (mmHg)Stage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QD
Baseline: SBP121.09 ± 7.18119.89 ± 10.36115.31 ± 3.81117.01 ± 10.09
Change at 24-hour interval between Days 8 and 15: SBP-4.08 ± 6.55-2.23 ± 3.95-0.67 ± 4.61-1.08 ± 2.90
Baseline: DBP71.02 ± 5.0373.09 ± 9.2270.48 ± 1.3571.08 ± 8.81
Change at 24-hour interval between Days 8 and 15: DBP-2.13 ± 3.93-1.55 ± 2.630.58 ± 3.42-1.90 ± 2.47
Baseline: Pulse pressure50.07 ± 4.7746.79 ± 5.3144.83 ± 3.2045.93 ± 2.07
Change at 24-hour interval between Days 8 and 15: Pulse pressure-1.94 ± 3.89-0.68 ± 2.32-1.25 ± 3.100.82 ± 0.77
Baseline: MAP88.27 ± 5.5089.05 ± 8.6985.45 ± 2.0586.85 ± 8.34
Change at 24-hour interval between Days 8 and 15: MAP-2.73 ± 4.42-1.98 ± 2.810.44 ± 3.46-1.63 ± 2.67
SecondaryChange From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C

The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in ABPM parameters (SBP, DBP, pulse pressure, MAP) during 24-hour interval between Days 8 and 15 is presented.

Time frame:
Baseline and for one 24-hour interval between Days 8 or 15
Reported as:
Mean · mmHg
Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C
mmHgStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QD
Baseline: SBP117.57 ± 9.99117.51 ± 8.05
Change at 24-hour interval between Days 8 and 15: SBP1.63 ± 6.831.22 ± 6.28
Baseline: DBP68.90 ± 7.5769.92 ± 5.96
Change at 24-hour interval between Days 8 and 15: DBP1.77 ± 4.830.83 ± 4.32
Baseline: Pulse pressure48.67 ± 7.4647.59 ± 7.58
Change at 24-hour interval between Days 8 and 15: Pulse pressure-0.14 ± 3.390.38 ± 2.70
Baseline: MAP85.97 ± 7.3386.30 ± 5.23
Change at 24-hour interval between Days 8 and 15: MAP1.21 ± 5.350.68 ± 4.56
SecondaryChange From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A

The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.

Time frame:
Baseline and for one 24-hour interval between Days 8 and 15
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A
beats per minute (bpm)Stage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QD
Baseline79.28 ± 7.0577.55 ± 8.2172.92 ± 6.8068.10 ± 6.48
Change at 24-hour interval between Days 8 and 15-0.90 ± 3.87-2.70 ± 5.38-5.75 ± 7.721.35 ± 7.70
SecondaryChange From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C

The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.

Time frame:
Baseline and for one 24-hour interval between Days 8 and 15
Reported as:
Mean · bpm
Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C
bpmStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QD
Baseline80.77 ± 9.0373.01 ± 10.65
Change at 24-hour interval between Days 8 and 15-0.95 ± 9.780.98 ± 4.21

Adverse events

Collected over From first dose up to Day 114. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage A: Setmelanotide 0.75 mg BID0/10 (0%)0/10 (0%)10/10 (100%)
Stage A: Setmelanotide 1.5 mg QD0/9 (0%)0/9 (0%)8/9 (88.9%)
Stage A: Placebo 0.75 mg BID0/3 (0%)0/3 (0%)2/3 (66.7%)
Stage A: Placebo 1.5 mg QD0/3 (0%)0/3 (0%)3/3 (100%)
Stage B: Setmelanotide 1.5 mg QD0/11 (0%)0/11 (0%)9/11 (81.8%)
Stage B: Placebo 1.5 mg QD0/6 (0%)0/6 (0%)3/6 (50%)
Stage C: Setmelanotide 2 mg QD0/29 (0%)1/29 (3.4%)29/29 (100%)
Stage C: Placebo 2 mg QD0/28 (0%)1/28 (3.6%)21/28 (75%)
Most frequent serious events
Most frequent serious events
EventStage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QDStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QDStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QD
Muscle strainInjury, poisoning and procedural complications0/100/90/30/30/110/60/291/28
Chest painGeneral disorders0/100/90/30/30/110/61/290/28
Most frequent other events
Showing 10 of 162
Most frequent other events
EventStage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QDStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QDStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QD
Skin hyperpigmentationSkin and subcutaneous tissue disorders7/106/91/30/38/110/626/292/28
NauseaGastrointestinal disorders3/106/90/31/36/111/617/293/28
HeadacheNervous system disorders5/104/90/30/34/112/616/299/28
VomitingGastrointestinal disorders1/104/90/30/33/111/610/293/28
Injection site pruritusGeneral disorders4/102/90/30/32/110/65/290/28
FatigueGeneral disorders3/100/91/30/30/110/610/292/28
DiarrhoeaGastrointestinal disorders1/100/90/30/33/110/610/294/28
Decreased appetiteMetabolism and nutrition disorders1/102/90/30/33/110/610/292/28
Abdominal painGastrointestinal disorders1/101/91/30/33/111/62/290/28
Dry skinSkin and subcutaneous tissue disorders2/102/91/30/30/110/62/290/28

Baseline characteristics

Safety Population included all participants who received at least 1 dose of study drug and had a post-baseline observation.

Age, Categorical
Age, Categorical(Participants)Stage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QDStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QDStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QDTotal
<=18 years000000000
Between 18 and 65 years10933116292899
>=65 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)Stage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QDStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QDStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QDTotal
Female631154211859
Male46226281040
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Stage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QDStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QDStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QDTotal
Hispanic or Latino1520123317
Not Hispanic or Latino9413104262582
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Stage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QDStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QDStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QDTotal
American Indian or Alaska Native000000101
Asian000000000
Native Hawaiian or Other Pacific Islander001000102
Black or African American84125411944
White241162131746
More than one race000000000
Unknown or Not Reported010000326
Region of Enrollment
Region of Enrollment(participants)Stage A: Setmelanotide 0.75 mg BIDStage A: Setmelanotide 1.5 mg QDStage A: Placebo 0.75 mg BIDStage A: Placebo 1.5 mg QDStage B: Setmelanotide 1.5 mg QDStage B: Placebo 1.5 mg QDStage C: Setmelanotide 2 mg QDStage C: Placebo 2 mg QDTotal
United States10933116292899
09

Study locations

2 sites
  • Dallas, Texas, United States
  • Madison, Wisconsin, United States
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Aug 2014, 7 months.

Results were first posted in Aug 2023, 9 years after primary completion. A results delay was requested in Apr 2015.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2014
First posted
Jan 20, 2014
StartActual
Jan 2014
Primary completionActual
Aug 2014
CompletionActual
Dec 2014
Results delay requested
Apr 13, 2015
Results first posted
Aug 7, 2023
Last update
Aug 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02041195
Responsible party
Sponsor
First posted
Jan 20, 2014
Start date
Jan 2014
Primary completion
Aug 2014
Completion
Dec 2014
Results posted
Aug 7, 2023
Last update
Aug 7, 2023

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion